arrow
C

Colin Baigent

universitat de vic-universitat central de catalunya (uvic-ucc)
H指数:99
被引数:9.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

恩格列净对EMPA-KIDNEY研究中尿液生物标志物的影响

2025-10-310
OAAI
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis

恩格列净对常规和探索性急性及慢性肾脏结局的影响:一项个体参与者水平的荟萃分析

2025-10-110
OAAI
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

2025年《2019 ESC/EAS血脂异常管理指南》聚焦更新版

2025-08-290
PRE
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Mach, F.; Koskinas, K.C.; Roeters van Lennep, J.E.; Tokgözoğlu, L.; Badimon, L.; Baigent, C.; Benn, M.; Binder, C.J.; Catapano, A.L.; De Backer, G.G.; 等. 2019年ESC/EAS血脂异常管理指南2025年重点更新版:由欧洲心脏病学会(ESC)和欧洲动脉粥样硬化学会(EAS)血脂异常管理工作组制定。Eur. Heart J. 2025, ehaf190. [Google Scholar] [CrossRef] [PubMed]

2025-08-0171
PRE
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

恩格列净对慢性肾病生活质量、医疗资源利用及成本的影响:EMPA-KIDNEY试验的健康经济学分析

2025-07-080
OA
Frailty, Multimorbidity, and Polypharmacy

虚弱、多发病和多重用药

2024-06-271
OAAI